JP2025131756A5 - - Google Patents
Info
- Publication number
- JP2025131756A5 JP2025131756A5 JP2025094518A JP2025094518A JP2025131756A5 JP 2025131756 A5 JP2025131756 A5 JP 2025131756A5 JP 2025094518 A JP2025094518 A JP 2025094518A JP 2025094518 A JP2025094518 A JP 2025094518A JP 2025131756 A5 JP2025131756 A5 JP 2025131756A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- liquid pharmaceutical
- stable liquid
- concentration
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962821661P | 2019-03-21 | 2019-03-21 | |
| US62/821,661 | 2019-03-21 | ||
| PCT/US2020/023795 WO2020191270A1 (en) | 2019-03-21 | 2020-03-20 | Stabilized formulations containing anti-il-33 antibodies |
| JP2021556435A JP7695887B2 (ja) | 2019-03-21 | 2020-03-20 | 抗ｉｌ－３３抗体を含有する安定化製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556435A Division JP7695887B2 (ja) | 2019-03-21 | 2020-03-20 | 抗ｉｌ－３３抗体を含有する安定化製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025131756A JP2025131756A (ja) | 2025-09-09 |
| JP2025131756A5 true JP2025131756A5 (https=) | 2026-01-26 |
Family
ID=70228884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556435A Active JP7695887B2 (ja) | 2019-03-21 | 2020-03-20 | 抗ｉｌ－３３抗体を含有する安定化製剤 |
| JP2025094518A Pending JP2025131756A (ja) | 2019-03-21 | 2025-06-06 | 抗ｉｌ－３３抗体を含有する安定化製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556435A Active JP7695887B2 (ja) | 2019-03-21 | 2020-03-20 | 抗ｉｌ－３３抗体を含有する安定化製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11596690B2 (https=) |
| EP (1) | EP3941522A1 (https=) |
| JP (2) | JP7695887B2 (https=) |
| KR (1) | KR20210141592A (https=) |
| CN (3) | CN119700966A (https=) |
| AU (1) | AU2020241882A1 (https=) |
| BR (1) | BR112021018727A2 (https=) |
| CA (1) | CA3133995A1 (https=) |
| CL (1) | CL2021002440A1 (https=) |
| CO (1) | CO2021011648A2 (https=) |
| EA (1) | EA202192568A1 (https=) |
| IL (2) | IL286024B2 (https=) |
| MA (1) | MA55362A (https=) |
| MX (1) | MX2021011137A (https=) |
| PH (1) | PH12021552092A1 (https=) |
| SA (1) | SA521430229B1 (https=) |
| SG (1) | SG11202109822XA (https=) |
| TW (2) | TW202519263A (https=) |
| WO (1) | WO2020191270A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| KR20230010239A (ko) * | 2020-05-11 | 2023-01-18 | 메디뮨 리미티드 | 항-il-33 항체의 제형물 |
| CN113603775B (zh) | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
| CN113842457B (zh) * | 2021-11-04 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 包含抗人白介素-33单克隆抗体的液体制剂 |
| WO2023077685A1 (zh) * | 2021-11-04 | 2023-05-11 | 江苏荃信生物医药股份有限公司 | 包含抗人白介素-33单克隆抗体的浓缩溶液的制备方法及液体制剂 |
| WO2026067832A1 (zh) * | 2024-09-30 | 2026-04-02 | 深圳市小分子新药创新中心有限公司 | 抗il-33单域抗体及其衍生物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| BRPI0108923B8 (pt) * | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GB0600351D0 (en) | 2006-01-10 | 2006-02-15 | Weston Terence E | Safe hypodermic needle |
| IE20080331A1 (en) | 2007-04-26 | 2009-07-08 | Trinity College Dublin | Products for altering cytokine activity and methods therefor |
| AU2008254704A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | IL-33 in inflammatory disease |
| WO2011031600A1 (en) | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
| BR112013008366B1 (pt) * | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| EP2768858B1 (en) * | 2011-10-18 | 2018-08-01 | Emory University | Antibodies directed against influenza |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| PL2892927T3 (pl) * | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| EA201890891A1 (ru) * | 2015-10-06 | 2018-09-28 | Ридженерон Фармасьютикалз, Инк. | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| KR20180106974A (ko) | 2017-03-16 | 2018-10-01 | 주식회사 엘지화학 | 항-tnf 알파 항체의 액상 제제 |
| WO2020227515A1 (en) * | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN112851814B (zh) * | 2020-03-17 | 2023-07-07 | 西安宇繁生物科技有限责任公司 | 一种靶向bcma的全人源单链抗体及其制备方法与应用 |
| EP4255451A4 (en) * | 2020-12-03 | 2025-01-01 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb-blocking antibodies |
| TW202237639A (zh) * | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
-
2020
- 2020-03-19 TW TW113138408A patent/TW202519263A/zh unknown
- 2020-03-19 TW TW109109133A patent/TWI861073B/zh active
- 2020-03-20 BR BR112021018727A patent/BR112021018727A2/pt unknown
- 2020-03-20 MA MA055362A patent/MA55362A/fr unknown
- 2020-03-20 CN CN202411908169.7A patent/CN119700966A/zh active Pending
- 2020-03-20 EA EA202192568A patent/EA202192568A1/ru unknown
- 2020-03-20 WO PCT/US2020/023795 patent/WO2020191270A1/en not_active Ceased
- 2020-03-20 CA CA3133995A patent/CA3133995A1/en active Pending
- 2020-03-20 CN CN202080021576.XA patent/CN113573733B/zh active Active
- 2020-03-20 AU AU2020241882A patent/AU2020241882A1/en active Pending
- 2020-03-20 EP EP20718107.4A patent/EP3941522A1/en active Pending
- 2020-03-20 IL IL286024A patent/IL286024B2/en unknown
- 2020-03-20 US US16/825,007 patent/US11596690B2/en active Active
- 2020-03-20 MX MX2021011137A patent/MX2021011137A/es unknown
- 2020-03-20 CN CN202411908014.3A patent/CN119700965A/zh active Pending
- 2020-03-20 PH PH1/2021/552092A patent/PH12021552092A1/en unknown
- 2020-03-20 JP JP2021556435A patent/JP7695887B2/ja active Active
- 2020-03-20 KR KR1020217033469A patent/KR20210141592A/ko active Pending
- 2020-03-20 IL IL317899A patent/IL317899A/en unknown
- 2020-03-20 SG SG11202109822X patent/SG11202109822XA/en unknown
-
2021
- 2021-09-02 CO CONC2021/0011648A patent/CO2021011648A2/es unknown
- 2021-09-05 SA SA521430229A patent/SA521430229B1/ar unknown
- 2021-09-20 CL CL2021002440A patent/CL2021002440A1/es unknown
-
2023
- 2023-02-03 US US18/105,772 patent/US20230346929A1/en active Pending
-
2025
- 2025-06-06 JP JP2025094518A patent/JP2025131756A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025131756A5 (https=) | ||
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| JP5946448B2 (ja) | 持続型ヒト成長ホルモン結合体液状製剤 | |
| TWI806150B (zh) | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 | |
| JP5153532B2 (ja) | モノクローナル抗体又はポリクローナル抗体の安定な凍結乾燥された医薬製剤 | |
| JP2019509311A5 (https=) | ||
| CA2794929A1 (en) | Concentrated protein formulations and uses thereof | |
| HRP20241131T1 (hr) | Visokokoncentrirane formulacije inhibitornih antitijela masp-2 niske viskoznosti, pribori i metode | |
| BR112012017979B1 (pt) | Formulações líquidas para conjugado de g-csf de ação prolongada | |
| JP2022174082A5 (https=) | ||
| JP2013500947A5 (https=) | ||
| JP2013517309A (ja) | タンパク質用の医薬製剤 | |
| US20090068196A1 (en) | Pharmaceutical formulation of an antibody against IL13Ralpha1 | |
| WO2021067775A1 (en) | Anto-connexin antibody formulations | |
| WO2020081408A1 (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| AU2013336206A1 (en) | Stable pharmaceutical composition of peginterferon alpha-2b | |
| JP7587507B2 (ja) | 製剤 | |
| ES2833099T3 (es) | Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica | |
| WO2009079837A1 (en) | A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein | |
| CN116249552A (zh) | 一种液体制剂及其应用 | |
| CN100542611C (zh) | 含有重组人血清白蛋白-干扰素α融合蛋白的注射用水剂 | |
| CN115518151B (zh) | 一种人类免疫缺陷病毒中和抗体制剂及其用途 | |
| RU2016152691A (ru) | Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα | |
| JPWO2020191270A5 (https=) | ||
| RU2024121592A (ru) | Лиофилизированная композиция, содержащая слитый белок, включающий α-галактозидазу А |